Variability in total serum IgE over 1 year in severe asthmatics

Renaud LouisCharles PiletteOlivier MichelAlain MichilsGuy BrusselleAntoine PoskinJan Van SchoorKris DenhaerynckStefaan VancayzeeleIvo Abraham and Sandra Gurdain

Abstract

Background

Immunoglobulin E (IgE) is the treatment target of omalizumab, a monoclonal antibody indicated in the treatment of severe allergic asthma. Long-term variability of serum total IgE (sIgEtot) in asthmatics remains poorly documented.

Methods

In this prospective study, sIgEtot levels were measured over 1 year at 7 time points in 41 severe asthmatics treated with high-dose of inhaled corticosteroids and long-acting β2 agonists. 33 patients were atopic based on at least one positive RAST to common aeroallergens. Patients were divided into three groups according to their baseline sIgEtot level: low (< 76 IU/mL; n = 10), intermediate (76–700 IU/mL; n = 20) or high (> 700 IU/mL; n = 11). Patients also completed the six-item Juniper Asthma Control Questionnaire (ACQ6). The sIgEtot variability and factors predictive for this variability were studied, as well as ACQ6 outcomes.

Results

The variation in sIgEtot level was mostly the consequence of between patient-variability, which represented 96%, 71% and 96% of the total variability in the low, intermediate and high sIgEtot subgroups, respectively. The residual within-patient variability was therefore limited. In 10/41 patients, sIgEtot levels increased or decreased, for at least one visit, beyond the predefined range of the subgroups to which they were assigned (< 76 IU/mL; 76–700 IU/mL; > 700 IU/mL). There was a significant but weak correlation between sIgEtot and ACQ6 score over all time points (r = 0.15, p = 0.02), but sIgEtot failed to associate with severe exacerbation. sIgEtot decreased by 3% with any additional year of age for the whole group (p = 0.01) and increased by 5% per one unit of allergen exposure score in atopic patients (p = 0.002).

Conclusion

In severe asthmatics, limited within-patient variability of sIgEtot levels was observed over 1 year as opposed to marked between-subject variability. sIgEtot decreases with age. Variation in sIgEtot weakly associates with asthma control but not with exacerbation.

Download PDF

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: World Health Organization releases guidelines for digital health adoption | MobiHealthNews… https://t.co/6DcfNz3h2R
5hreplyretweetfavorite
Interasma RT @worldallergy: WAO and the French Allergy Society (SFA) invite you to submit an abstract for the World Allergy Congress 2019 that will b…
14hreplyretweetfavorite
Interasma RT @Aller_MD: “Association of Rhinovirus C Bronchiolitis and Immunoglobulin E Sensitization During Infancy With Development of Recurrent Wh…
14hreplyretweetfavorite
Interasma RT @Aller_MD: “Lentiviral vector gene therapy with low-exposure, targeted busulfan in infants with newly diagnosed SCID-X1 resulted in mult…
14hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma